Specific IgE and Basophil Activation Test by Microarray: A Promising Tool for Diagnosis of Platinum Compound Hypersensitivity Reactions

• Published in: International journal of molecular sciences Vol. 25; no. 7; p. 3890
• Main Authors: Fernández-Lozano, Carlos, Rita, Claudia Geraldine, Barra-Castro, Alicia, de la Hoz Caballer, Belén, Roldán, Ernesto, Pueyo López, Cristina, Martinez-Botas, Javier, Berges-Gimeno, María Pilar
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-04-2024
• Subjects: Allergies; Animals; Antineoplastic Agents, Alkylating; basophil activation test; Basophil Degranulation Test; Cancer; Carboplatin - adverse effects; drug allergies; Drug Hypersensitivity - diagnosis; Drugs; Flow cytometry; Histamine; Humans; hypersensitivity reaction; Hypersensitivity, Immediate; Immunoassay; Immunoglobulin E; microarray; Oncology, Experimental; Patients; Platinum Compounds; Polychaeta; Radiation-Sensitizing Agents; Silicon compounds; Standard scores; Steroids; Thiones; Spain; basophil activation test; drug allergies; microarray; hypersensitivity reaction; platinum compounds
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25073890

Drug hypersensitivity reactions (DHRs) to platinum-based compounds (PCs) are on the rise, and their personalized and safe management is essential to enable first-line treatment for these cancer patients. This study aimed to evaluate the usefulness of the basophil activation test by flow cytometry (BAT-FC) and the newly developed sIgE-microarray and BAT-microarray in diagnosing IgE-mediated hypersensitivity reactions to PCs. A total of 24 patients with DHRs to PCs (20 oxaliplatin and four carboplatin) were evaluated: thirteen patients were diagnosed as allergic with positive skin tests (STs) or drug provocation tests (DPTs), six patients were diagnosed as non-allergic with negative STs and DPTs, and five patients were classified as suspected allergic because DPTs could not be performed. In addition, four carboplatin-tolerant patients were included as controls. The BAT-FC was positive in 2 of 13 allergic patients, with a sensitivity of 15.4% and specificity of 100%. However, the sIgE- and BAT-microarray were positive in 11 of 13 DHR patients, giving a sensitivity of over 84.6% and a specificity of 90%. Except for one patient, all samples from the non-allergic and control groups were negative for sIgE- and BAT-microarray. Our experience indicated that the sIgE- and BAT-microarray could be helpful in the endophenotyping of IgE-mediated hypersensitivity reactions to PCs and may provide an advance in decision making for drug provocation testing.